CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 297 enrolled
Drug / intervention
INDICAID™ COVID-19 Rapid Antigen Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04904510
NCT04904510N/ACompleted
CompareCT.gov

Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing

University of California, Los Angeles·observational·Posted May 27, 2021·Updated Feb 15, 2023

In Brief

An observational study evaluating INDICAID™ COVID-19 Rapid Antigen Test for Covid19. Completed, enrolled 297 participants across 1 site.

Detailed Summary

The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 27, 2021
Enrollment StartNov 20, 2020
Primary CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.1 years ago

Interventions

INDICAID™ COVID-19 Rapid Antigen Testother

The diagnostic assay will be compared to a EUA SARS-CoV-2 assay